Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Electromed Posts 17% Gain in Fiscal Q4

TheMotleyFool 
1 0 26.08.25
Electromed Posts 17% Gain in Fiscal Q4
 

Electromed (NYSEMKT:ELMD), a medical device company specializing in airway clearance therapy, reported record financial results for the quarter and fiscal year ended August 26, 2025. The company’s revenue rose to $17.4 million, a 17.3% increase from the same period last year, and diluted earnings per share (GAAP) reached $0.25, up from $0.20 in Q4 FY2024. These results surpassed the growth rate of the previous quarter, reflecting strong momentum in the core business. Electromed saw improvement across key profitability metrics, including a gross margin gain and significant growth in operating income. The quarter capped a strong year of operational and financial progress, though management offered no forward-looking guidance.

Electromed develops and markets medical devices in the respiratory care field. Its main product is the SmartVest System, which delivers High Frequency Chest Wall Oscillation (HFCWO) therapy to help patients clear mucus from their lungs. The system is primarily used by patients suffering from chronic lung conditions such as bronchiectasis, cystic fibrosis, and neuromuscular conditions such as cerebral palsy and ALS.

The company's business relies heavily on its direct-sales focused homecare model. Electromed’s strategy centers on sales rep productivity, expanding its reach in underpenetrated markets, and driving adoption of SmartVest through clinical education, reimbursement support, and patient outreach. Maintaining product effectiveness, regulatory compliance, and favorable reimbursement conditions are critical success factors for the company’s growth.

Continue reading


Source Fool.com

ALS Ltd Stock

€12.20
-0.810%
ALS Ltd shows a slight decrease today, losing -€0.100 (-0.810%) compared to yesterday.

Show more
Like: 0
ELMD
Share

Comments

I was diagnosed with Bronchiectasis four years ago. For over two years, I relied on prescription medications and therapies, but unfortunately, the symptoms continued to worsen. My breathing became more laboured, and I experienced increasing fatigue and shortness of breath with even minimal activity. Last year, out of desperation and hope, I decided to try an herbal treatment program from NaturePath Herbal Clinic. Honestly, I was skeptical at first, but within a few months of starting the treatment, I began to notice real changes. My breathing became easier, the tightness in my chest eased, and I felt more energetic and capable in my daily life. Incredibly, I also regained much of my stamina and confidence. It’s been a life-changing experience I feel more like myself again, better than I’ve felt in years. If you or a loved one is struggling with Bronchiectasis, I truly recommend looking into their natural approach. You can visit their website at www.naturepathherbalclinic.com
Show more

Eliz 
0
Report Share
03.09.25
Show more
Not a member yet? Sign up for free!